Fatigue News and Research

RSS

Ethnicity, depression, lack of exercise are major risk factors for chronic fatigue syndrome

Chronic fatigue syndrome (CFS) is characterized by unexplained and debilitating tiredness and is associated with headaches, disrupted sleep, muscle pain and difficulty in concentrating. New research published by BioMed Central's open access journal BMC Medicine shows that ethnicity, depression, lack of exercise or social support, and social difficulties are major risk factors for CFS.

21 Mar 2011

Ibuprofen - painkiller toxicity warning

In a recent development, doctors have warned regarding the possibly toxicities of common pain killer Ibuprofen adding that it can lead to a potentially fatal condition which can be triggered, in rare cases, by even a standard dose. The condition in question is called renal tubular acidosis (RTA). The research is published in the Medical Journal of Australia.

21 Mar 2011

Expert says celebrity addiction stories can serve as warning about drug abuse effects

Stories about celebrities with alleged drug problems make entertaining fodder for the media. But to addiction expert Dr. Gregory Jantz, founder of The Center for Counseling and Health Resources and author of several books on addiction, these well-publicized stories of celebrity drug abuse and addiction can serve as a serious warning.

17 Mar 2011

PsiOxus commences MT-102 Phase II study for treatment of cancer- and age-related wasting

PsiOxus Therapeutics, Ltd. announced initiation of a Phase II study of MT-102, a small molecule therapeutic for the treatment of cancer- and age-related wasting. MT-102 is being developed to reverse the effects of cachexia, a wasting disease that accompanies cancer, heart failure, COPD, renal failure, cirrhosis and rheumatoid arthritis, and that is associated with significant morbidity and mortality.

17 Mar 2011

Older adults in public housing suffer fatigue and chronic related conditions

Location really does matter to older adults' health, according to a new study that found those living in public housing fare poorly and suffer more from fatigue and chronic, related conditions than those in other community dwellings.

16 Mar 2011

Insight into Lyme disease

Researchers recently developed novel diagnostic tools able to distinguish between the various strains of bacteria responsible for causing Lyme disease. For more than a decade, only one strain of B. burgdorferi had been sequenced, and although that helped research efforts, it was not sufficient to understand the relationship between geographic variations in strains and disease characteristics.

16 Mar 2011

Researchers identify genetic cause of magnesium deficiency

Researchers and scientists of the Charité - Universitätsmedizin Berlin, in cooperation with the Max Delbrück Center for Molecular Medicine, and colleagues from the Netherlands, Belgium, Switzerland and the Czech Republic have succeeded in identifying a genetic cause of magnesium deficiency.

16 Mar 2011

Hospice and Palliative care

The word hospice originated from the Latin hospitium, which means "to host or offer a place of shelter." In 2009, an estimated 1.56 million patients, more than 40 percent of deaths, received hospice services in the United States.

14 Mar 2011

New drug for Lupus approved

A new drug for lupus has won U.S. approval. The drug, Benlysta from Human Genome Sciences Inc., is administered once a month intravenously.

12 Mar 2011

Scientific advances at Scripps Research lay foundation for new lupus drug Benlysta

Scientific advances at The Scripps Research Institute were key to laying the foundation for the new drug Benlysta® (belimumab), approved today by the U.S. Food and Drug Administration. Benlysta®, which treats the most common type of lupus, is the first in a new class of pharmaceuticals that prevents the body from attacking its own critical tissues.

11 Mar 2011

Sanofi-aventis, Regeneron announce results of VEGF Trap Phase III trial in second-line NSCLC

Sanofi-aventis and Regeneron Pharmaceuticals, Inc. announced results from the Phase III VITAL trial evaluating the investigational agent aflibercept (VEGF Trap) for the second-line treatment of non-small cell lung cancer (NSCLC).

11 Mar 2011

First U.S. catheter ablation procedure for treatment of AF performed at Mount Sinai

The Mount Sinai Medical Center has become the first hospital in the United States to perform a cardiac catheterization procedure using the TactiCath force-sensing ablation catheter for the treatment of symptomatic paroxysmal atrial fibrillation, or periodic rapid and irregular heartbeats.

11 Mar 2011

Researchers use new computer model to learn about toe strength

Researchers are using a new model to learn more about how toe strength can determine how far people can lean while keeping their balance.

11 Mar 2011

Human Genome Sciences receives FDA approval for Benlysta to treat lupus

The U.S. Food and Drug Administration today approved Benlysta to treat patients with active, autoantibody-positive lupus who are receiving standard therapy, including corticosteroids, antimalarials, immunosuppressives, and nonsteroidal anti-inflammatory drugs.

9 Mar 2011

Vertex to present telaprevir and VX-222 study results against hepatitis C at EASL annual meeting

Vertex Pharmaceuticals Incorporated announced today that 15 abstracts on the company's medicines in development for hepatitis C, including its protease inhibitor, telaprevir, and polymerase inhibitor, VX-222, were accepted for presentation at the 46th Annual Meeting of the European Association for the Study of the Liver in Berlin, Germany, March 30 to April 3, 2011.

9 Mar 2011

Colonoscopy can serve as effective tool to reduce colorectal cancer death

In recognition of National Colorectal Cancer Awareness Month during March, GIE: Gastrointestinal Endoscopy has published a special issue for March on colonoscopy and colorectal cancer.

9 Mar 2011

Recent rituximab trial with TNF inhibitors reports no new safety risks in patients with RA

A recent trial of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis found the safety profile to be consistent with other RA trials with TNF inhibitors.

8 Mar 2011

New Lupus drug marching towards approval

A new drug for lupus from the Human Genome Sciences Inc is all set to get clearance in the US this week. If all goes through, this drug will offer patients the first approved treatment option in a half-century, setting the manufacturer up for huge sales.

7 Mar 2011

Core Performance uses IBM software to help consumers reach their fitness goals

IBM today announced that a leading provider of corporate fitness services is using business rules software to customize individual workouts to help consumers reach their fitness goals in the New Year.

5 Mar 2011

Football player announces release of new pre-workout intensity supplement

Ray Lewis, one of the greatest players ever to step on a football field, today announced the release of an all new pre-workout intensity supplement, called Power Fuel, which will feature Lewis on its packaging and contain a powerful custom ingredient blend named in his honor.

5 Mar 2011

Fatigue News and Research

Ethnicity, depression, lack of exercise are major risk factors for chronic fatigue syndrome

Ibuprofen - painkiller toxicity warning

Expert says celebrity addiction stories can serve as warning about drug abuse effects

PsiOxus commences MT-102 Phase II study for treatment of cancer- and age-related wasting

Older adults in public housing suffer fatigue and chronic related conditions

Insight into Lyme disease

Researchers identify genetic cause of magnesium deficiency

Hospice and Palliative care

New drug for Lupus approved

Scientific advances at Scripps Research lay foundation for new lupus drug Benlysta

Sanofi-aventis, Regeneron announce results of VEGF Trap Phase III trial in second-line NSCLC

First U.S. catheter ablation procedure for treatment of AF performed at Mount Sinai

Researchers use new computer model to learn about toe strength

Human Genome Sciences receives FDA approval for Benlysta to treat lupus

Vertex to present telaprevir and VX-222 study results against hepatitis C at EASL annual meeting

Colonoscopy can serve as effective tool to reduce colorectal cancer death

Recent rituximab trial with TNF inhibitors reports no new safety risks in patients with RA

New Lupus drug marching towards approval

Core Performance uses IBM software to help consumers reach their fitness goals

Football player announces release of new pre-workout intensity supplement

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News